⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12699753 | 1.00 | — | — | |
| SCHEMBL584094 | 1.00 | — | — | |
| Methane SCHEMBL10516513 | 0.98 | CHRNB2 (0.52) | — | |
| Hydrochloric Acid SCHEMBL17364117 | 0.98 | CHRNB2 (0.52) | — | |
| Hydrochloric Acid SCHEMBL3911969 | 0.98 | CHRNB2 (0.52) | — | |
| Hydrochloric Acid SCHEMBL594534 | 0.98 | CHRNB2 (0.52) | — | |
| Acetic Acid Methyl Ester SCHEMBL9148923 | 0.94 | CHRNB2 (0.48) | — | |
| SCHEMBL4673135 | 0.88 | SLC6A1 (0.59) | — | |
| SCHEMBL13598498 | 0.88 | SLC6A1 (0.59) | — | |
| SCHEMBL763374 | 0.88 | SLC6A1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-12 | — | — | US | disclosed |
| US-12624003-B2 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4267117-B1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORP (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4694981-A1 | HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS | Aurigene Oncology Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| WO-2025134078-A1 | ORGANIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMS) | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-06-26 | — | — | WO | disclosed |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| CN-1950375-A | Glucocorticoid receptor modulator compounds and methods- utility | LIGAND PHARM INC (US) | 2007-04-18 | — | — | CN | disclosed |
| WO-2006076246-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |